BBNX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Beta Bionics's net margin of --. Beta Bionics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Beta Bionics has a consensus price target of $23.56, signalling upside risk potential of 86.06%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Perspective Therapeutics has higher upside potential than Beta Bionics, analysts believe Perspective Therapeutics is more attractive than Beta Bionics.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Beta Bionics's net income of -- is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Beta Bionics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -- compared to Beta Bionics's net margin of -5.14%. Beta Bionics's return on equity of -- beat Integer Holdings's return on equity of 4.85%.

Beta Bionics has a consensus price target of $23.56, signalling upside risk potential of 86.06%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 27%. Given that Beta Bionics has higher upside potential than Integer Holdings, analysts believe Beta Bionics is more attractive than Integer Holdings.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Integer Holdings quarterly revenues of $437.4M. Beta Bionics's net income of -- is lower than Integer Holdings's net income of -$22.5M. Notably, Beta Bionics's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 55.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 2.36x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -- compared to Beta Bionics's net margin of 6.22%. Beta Bionics's return on equity of -- beat Insulet's return on equity of 36.9%.

Beta Bionics has a consensus price target of $23.56, signalling upside risk potential of 86.06%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Beta Bionics has higher upside potential than Insulet, analysts believe Beta Bionics is more attractive than Insulet.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Insulet quarterly revenues of $569M. Beta Bionics's net income of -- is lower than Insulet's net income of $35.4M. Notably, Beta Bionics's price-to-earnings ratio is -- while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of -- compared to Beta Bionics's net margin of -55.69%. Beta Bionics's return on equity of -- beat Tandem Diabetes Care's return on equity of -81.14%.

Beta Bionics has a consensus price target of $23.56, signalling upside risk potential of 86.06%. On the other hand Tandem Diabetes Care has an analysts' consensus of $31.70 which suggests that it could grow by 101.27%. Given that Tandem Diabetes Care has higher upside potential than Beta Bionics, analysts believe Tandem Diabetes Care is more attractive than Beta Bionics.

Beta Bionics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.763%.

Beta Bionics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Beta Bionics quarterly revenues are --, which are smaller than Tandem Diabetes Care quarterly revenues of $234.4M. Beta Bionics's net income of -- is lower than Tandem Diabetes Care's net income of -$130.6M. Notably, Beta Bionics's price-to-earnings ratio is -- while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics is -- versus 1.05x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.